Literature DB >> 2543285

In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus.

T Inoue1, K Tsushita, T Itoh, M Ogura, T Hotta, M Saneyoshi, S Yoshida, H Saitoh, Y Tomoda, Y Nagai.   

Abstract

3'-Azido-2',3'-dideoxythymidine is known to cause severe anemia and neutropenia. Although these are rare for 2',3'-dideoxycytidine, it frequently impairs thrombocytogenesis. These differential myelossuppressive features correlated well with the in vitro toxicities of the drugs for a megakaryoblastic cell line and for colony formation of erythroid and granulocytic cells.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2543285      PMCID： PMC172483          DOI： 10.1128/AAC.33.4.576

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; M Dalal; H Mitsuya; J B McMahon; M Nadkarni; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1986-07-01       Impact factor: 5.858

2.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

3.  Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues.

Authors:  C H Kim; V E Marquez; S Broder; H Mitsuya; J S Driscoll
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

4.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

6.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

7.  Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

Authors:  J P Sommadossi; R Carlisle
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

8.  3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.

Authors:  P Herdewijn; J Balzarini; E De Clercq; R Pauwels; M Baba; S Broder; H Vanderhaeghe
Journal:  J Med Chem       Date:  1987-08       Impact factor: 7.446

9.  Functional and morphological differentiation induction of a human megakaryoblastic leukemia cell line (MEG-01s) by phorbol diesters.

Authors:  M Ogura; Y Morishima; M Okumura; T Hotta; S Takamoto; R Ohno; N Hirabayashi; H Nagura; H Saito
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321
View more
  9 in total

1.  Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus.

Authors:  Michael K Lo; Franck Amblard; Mike Flint; Payel Chatterjee; Mahesh Kasthuri; Chengwei Li; Olivia Russell; Kiran Verma; Leda Bassit; Raymond F Schinazi; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2020-01-11       Impact factor: 5.970

2.  3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA.

Authors:  J A Harrington; J E Reardon; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 3.  Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.

Authors:  A P Lea; D Faulds
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

4.  In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model.

Authors:  P J Polas; C L Swenson; R Sams; C M Cheney; K A Hayes; M J Tarr; G J Kociba; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.

Authors:  R E Dornsife; M H St Clair; A T Huang; T J Panella; G W Koszalka; C L Burns; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 6.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

7.  The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy.

Authors:  D T Chiu; P H Duesberg
Journal:  Genetica       Date:  1995       Impact factor: 1.082

Review 8.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

9.  Neurotoxic effects of AZT on developing and adult neurogenesis.

Authors:  Meryem Demir; Eric D Laywell
Journal:  Front Neurosci       Date:  2015-03-20       Impact factor: 4.677
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.